All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Ipilimumab for patients with relapse after allogeneic transplantation
The anti-CTLA-4 monoclonal antibody, ipilimumab, has been used to effectively improve overall survival in two phase III studies involving patients with advanced melanoma1. Following on from the success in melanoma, Davids M.S, from the Dana-Farber Cancer Institute et al., hypothesized that immune checkpoint blockade, established by targeting CTLA-4 with ipilimumab, may induce a graft-versus-tumor effect in patients with relapse after allogeneic HSCT and lead to a clinical response.2
Davids MS, et al., conducted a phase 1/1b multicenter, open-label, investigator-initiated study to determine the MTD, the safety and efficacy of ipilimumab in patients with relapsed hematologic cancer (12 AML patients out of 28) after allogeneic hematopoietic stem-cell transplantation (HSCT). The results were published in N Engl J Med in July 2016.
The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines and was registered at ClinicalTrials.gov (NCT01822509).
The key findings were:
- No objective response was seen at a dose of 3 mg/kg, whereas 10 mg/kg induced OR in 7 patients out of 22. The 5 CR was observed in patients with extra-medullary AML (4) and in one patient with MDS developing into AML. This patient remained in CR for 16 months.
- Ipilimumab was active in patients with relapsed hematologic cancers after allogeneic HSCT, but some patients experienced graft versus host disease (GVHD) (2 chronic GVHD of the liver and one case of grade II acute GVHD of the gut) or irAEs (grade 2 immune thrombocytopenia (1), grade 2 pneumonitis (1) and grade 3 colitis and pneumonitis grade 4 (1). This last patient died 42 days after receiving the initial dose of ipilimumab.
These data warrant the further investigation of the use of ipilimumab for patients with relapsed hematologic malignancies after transplantation, however, monitoring for immune-related adverse events is required.
References